Abstract
ObjectiveIn multiple myeloma patients, daratumumab is preferably injected subcutaneously. The summary of product characteristics of daratumumab subcutaneous injection solution specifies physicochemical stability for the prepared syringe for 24 hours at...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have